Abbott Laboratories (NYSE:ABT) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 0.49%.
Abbott Laboratories Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased 59.22% to $0.42 in the quarter versus EPS of $1.03 in the year-earlier quarter.
Revenue: Decreased 43.13% to $5.38 billion from the year-earlier quarter.
Actual vs. Wall St. Expectations: Abbott Laboratories reported adjusted EPS income of $0.42 per share. By that measure, the company beat the mean analyst estimate of $0.41. It missed the average revenue estimate of $5.42 billion.
Quoting Management: “Strong performance in Nutrition and Diagnostics, as well as overall results in emerging markets, led our sales growth this quarter,” said Miles D. White, chairman and chief executive officer, Abbott. “We had significant new product and geographic expansion activity during the quarter that positions Abbott well for continued growth.”
Key Stats (on next page)…
Revenue decreased 50.37% from $10.84 billion in the previous quarter. EPS decreased 72.19% from $1.51 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.49 to a profit $0.44. For the current year, the average estimate has moved up from a profit of $1.97 to a profit of $2.01 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)